|

Trastuzumab/Hyaluronidase-oysk Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20 +1 more

Pipeline

Phase 3: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor1
  • Endometrial Serous Adenocarcinoma1
  • Endometrial Undifferentiated Carcinoma1
  • Endometrial Mixed Cell Adenocarcinoma1
  • Endometrial Endometrioid Adenocarcinoma1

Birmingham, Alabama1 trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

University of Alabama at Birmingham Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.